Subscribe
shutterstock_1826152031_lev_radin
Lev Radin / Shutterstock.com
24 August 2021Big PharmaAlex Baldwin

Regeneron asks court to dismiss COVID-19 tech patent suit

Regeneron wants a Manhattan district court to toss a lawsuit that claims it infringed on patents in the development and testing of COVID-19 treatments.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
A deep dive into Regeneron v Kymab
8 March 2021   On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Americas
US court backs Sanofi and Regeneron in Amgen suit
29 August 2019   A US judge yesterday, August 28 ruled in favour of Sanofi and Regeneron in the pharmaceutical companies’ long-running patent dispute with Amgen over the cholesterol drug Praluent.
Big Pharma
PTAB grants IPR of Regeneron Eylea patents
11 November 2021   The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
A deep dive into Regeneron v Kymab
8 March 2021   On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Americas
US court backs Sanofi and Regeneron in Amgen suit
29 August 2019   A US judge yesterday, August 28 ruled in favour of Sanofi and Regeneron in the pharmaceutical companies’ long-running patent dispute with Amgen over the cholesterol drug Praluent.
Big Pharma
PTAB grants IPR of Regeneron Eylea patents
11 November 2021   The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.

More on this story

Big Pharma
A deep dive into Regeneron v Kymab
8 March 2021   On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Americas
US court backs Sanofi and Regeneron in Amgen suit
29 August 2019   A US judge yesterday, August 28 ruled in favour of Sanofi and Regeneron in the pharmaceutical companies’ long-running patent dispute with Amgen over the cholesterol drug Praluent.
Big Pharma
PTAB grants IPR of Regeneron Eylea patents
11 November 2021   The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility